

**UNDERSTANDING REGARDING
ARTICLE 2 OF ANNEX 26-A ON
TRANSPARENCY AND PROCEDURAL FAIRNESS FOR
PHARMACEUTICAL PRODUCTS AND MEDICAL DEVICES**

February 4, 2016

The Governments of the Republic of Singapore and the Republic of Peru have reached the following understanding, concerning Annex 26-A (Transparency and Procedural Fairness for Pharmaceutical Products and Medical Devices) contained in Chapter 26 (Transparency and Anti-Corruption) of the Trans-Pacific Partnership Agreement signed this day, February 4, 2016:

The Parties recognise that with regard to Article 2 (Principles), it is understood that “high-quality health care” does not refer to specific final outcomes in a Party’s health care system, including the selection of specific pharmaceutical products.

This understanding is set out in the English and Spanish languages. In the event of any divergence between the texts, the English language version shall prevail.

FOR THE GOVERNMENT OF THE
REPUBLIC OF SINGAPORE:



Lim Hng Kiang
Minister for Trade and Industry (Trade)
Republic of Singapore

FOR THE GOVERNMENT OF THE
REPUBLIC OF PERU:



Magali Silva Velarde-Álvarez
Minister of Foreign Trade and Tourism
Republic of Peru